Literature DB >> 6212203

Dose dependence of piperacillin pharmacokinetics.

T Bergan, J D Williams.   

Abstract

Pharmacokinetics were evaluated for piperacillin given as doses of 15, 30 and 60 mg/kg body weight to 12 healthy volunteers subdivided into three groups which were each given different dosage levels. For the 15, 30 and 60 mg/kg doses, the serum half-lives were 0.8, 1.0 and 0.9 h, and the disposition phase distribution volume coefficients, delta d. beta, 0.31, 0.30, ad 0.25 l/kg. The total body clearances for the three doses normalized to 70 kg body weight were 18.53, 14.00 and 13.53 l/h for the 15, 30 and 60 mg/kg doses, respectively. The corresponding values for the total area under the curves per 1.0 g dose were 57.1, 75.0 and 79.6 micrograms/ml. The urinary elimination of the antibiotic corresponding to the antimicrobial activity of unchanged drug rose from 50.0 to 71.3% of the dose, for a dose increment of 15 to 60 mg/kg. These results document that piperacillin is subject to dose-dependent pharmacokinetics. Capacity-limited kinetics is a property shared by other ureidopenicillins.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6212203     DOI: 10.1159/000238070

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  18 in total

1.  Nonlinear pharmacokinetics of piperacillin in healthy volunteers--implications for optimal dosage regimens.

Authors:  Jürgen B Bulitta; Martina Kinzig; Verena Jakob; Ulrike Holzgrabe; Fritz Sörgel; Nicholas H G Holford
Journal:  Br J Clin Pharmacol       Date:  2010-11       Impact factor: 4.335

2.  Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation.

Authors:  Thomas P Lodise; Ben Lomaestro; Keith A Rodvold; Larry H Danziger; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

3.  Comparative pharmacokinetics of azlocillin and piperacillin in normal adults.

Authors:  P A Colaizzi; R E Polk; W J Poynor; A C Raffalovich; E A Cefali; L A Beightol
Journal:  Antimicrob Agents Chemother       Date:  1986-05       Impact factor: 5.191

4.  Pharmacokinetics and pharmacodynamics of two multiple-dose piperacillin-tazobactam regimens.

Authors:  D J Occhipinti; S L Pendland; L L Schoonover; E B Rypins; L H Danziger; K A Rodvold
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

5.  Pharmacodynamics of piperacillin alone and in combination with tazobactam against piperacillin-resistant and -susceptible organisms in an in vitro model of infection.

Authors:  A H Strayer; D H Gilbert; P Pivarnik; A A Medeiros; S H Zinner; M N Dudley
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

6.  Comparative pharmacokinetics of apalcillin and piperacillin.

Authors:  H Lode; A Elvers; P Koeppe; K Borner
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

Review 7.  Antibiotic pharmacokinetics in cystic fibrosis. Differences and clinical significance.

Authors:  R de Groot; A L Smith
Journal:  Clin Pharmacokinet       Date:  1987-10       Impact factor: 6.447

8.  Population pharmacokinetics of piperacillin at two dose levels: influence of nonlinear pharmacokinetics on the pharmacodynamic profile.

Authors:  Cornelia B Landersdorfer; Jurgen B Bulitta; Carl M J Kirkpatrick; Martina Kinzig; Ulrike Holzgrabe; George L Drusano; Ulrich Stephan; Fritz Sörgel
Journal:  Antimicrob Agents Chemother       Date:  2012-08-20       Impact factor: 5.191

9.  Single-dose pharmacokinetics of piperacillin and tazobactam in infants and children.

Authors:  M D Reed; J Goldfarb; T S Yamashita; E Lemon; J L Blumer
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

10.  Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers.

Authors:  J B Bulitta; S B Duffull; M Kinzig-Schippers; U Holzgrabe; U Stephan; G L Drusano; F Sörgel
Journal:  Antimicrob Agents Chemother       Date:  2007-05-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.